Jingzhou Hou

Jingzhou Hou practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Jingzhou Hou's NPI, 1053478131, was assigned on January 2, 2007. Jingzhou Hou holds Pennsylvania license MD430543.

Jingzhou Hou's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Jingzhou Hou's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Jingzhou Hou is also affiliated with UPMC Presbyterian. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Jingzhou Hou to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Jingzhou Hou practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Jingzhou Hou's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Jingzhou Hou is licensed in Pennsylvania.

CMS data shows 1,030 Medicare services from Jingzhou Hou across 6 procedure codes in 2024, for 246 Medicare patients. Medicare paid $95,155 for them.

CMS counts 246 Medicare patients who saw Jingzhou Hou in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Jingzhou Hou's median patient age at 73, with 48% women.

In 2024, Jingzhou Hou wrote 1,143 Medicare Part D claims for 179 patients. 71% of them were for generic drugs. CMS names the drug for 899 of them, across 27 drugs with 11 or more claims each, at $2,510,824 in total drug cost. In 2023, CMS named 881 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Jingzhou Hou for performance year 2024, reported as part of a group. Jingzhou Hou accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Jingzhou Hou as offering telehealth.

Dmand AI links 1 paper to Jingzhou Hou in 2015. Jingzhou Hou's most frequent co-authors are Zihai Li, MD, Weijing Sun, MD and Ruirong Yuan, MD.

Dmand AI links Jingzhou Hou to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute and Leukemia, Myeloid. Open Payments lists research payments to Jingzhou Hou that name 2 trials.

CMS Open Payments shows 193 general payments to Jingzhou Hou from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $68,962. It also lists 9 research payments totaling $2,847 from 2016 to 2025, naming 2 clinical trials.